1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Brain Tumor Drugs Market, By Therapy
5.1 Introduction
5.2 Targeted Therapy
5.3 Chemotherapy
5.4 Immunotherapy
5.5 Other Therapies
6 Global Brain Tumor Drugs Market, By Indication
6.1 Introduction
6.2 Pituitary Tumors
6.3 Meningioma
6.4 Glioblastoma
6.5 Glioma
7 Global Brain Tumor Drugs Market, By Drugs
7.1 Introduction
7.2 Bevacizumab
7.3 Temozolomide
7.4 Other Drugs
8 Global Brain Tumor Drugs Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 F. Hoffmann-La Roche Ltd
10.2 Merck & Co. Inc.
10.3 Pfizer Inc
10.4 Novartis AG
10.5 Amneal Pharmaceuticals LLC.
10.6 NextSource Pharmaceuticals, LLC
10.7 Amgen Inc
10.8 Bristol-Myers Squibb
10.9 Emcure Pharmaceuticals
10.10 AstraZeneca
List of Tables
Table 1 Global Brain Tumor Drugs Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 3 Global Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 4 Global Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 5 Global Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 6 Global Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 7 Global Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 8 Global Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 9 Global Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 10 Global Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 11 Global Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 12 Global Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 13 Global Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 14 Global Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 15 Global Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 16 North America Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 17 North America Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 18 North America Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 19 North America Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 20 North America Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 21 North America Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 22 North America Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 23 North America Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 24 North America Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 25 North America Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 26 North America Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 27 North America Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 28 North America Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 29 North America Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 30 North America Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 31 Europe Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 32 Europe Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 33 Europe Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 34 Europe Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 35 Europe Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 36 Europe Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 37 Europe Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 38 Europe Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 39 Europe Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 40 Europe Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 41 Europe Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 42 Europe Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 43 Europe Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 44 Europe Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 45 Europe Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 46 Asia Pacific Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 47 Asia Pacific Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 48 Asia Pacific Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 49 Asia Pacific Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 50 Asia Pacific Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 51 Asia Pacific Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 52 Asia Pacific Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 53 Asia Pacific Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 54 Asia Pacific Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 55 Asia Pacific Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 56 Asia Pacific Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 57 Asia Pacific Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 58 Asia Pacific Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 59 Asia Pacific Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 60 Asia Pacific Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 61 South America Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 62 South America Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 63 South America Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 64 South America Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 65 South America Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 66 South America Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 67 South America Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 68 South America Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 69 South America Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 70 South America Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 71 South America Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 72 South America Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 73 South America Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 74 South America Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 75 South America Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
Table 76 Middle East & Africa Brain Tumor Drugs Market Outlook, By Country (2020-2028) ($MN)
Table 77 Middle East & Africa Brain Tumor Drugs Market Outlook, By Therapy (2020-2028) ($MN)
Table 78 Middle East & Africa Brain Tumor Drugs Market Outlook, By Targeted Therapy (2020-2028) ($MN)
Table 79 Middle East & Africa Brain Tumor Drugs Market Outlook, By Chemotherapy (2020-2028) ($MN)
Table 80 Middle East & Africa Brain Tumor Drugs Market Outlook, By Immunotherapy (2020-2028) ($MN)
Table 81 Middle East & Africa Brain Tumor Drugs Market Outlook, By Other Therapies (2020-2028) ($MN)
Table 82 Middle East & Africa Brain Tumor Drugs Market Outlook, By Indication (2020-2028) ($MN)
Table 83 Middle East & Africa Brain Tumor Drugs Market Outlook, By Pituitary Tumors (2020-2028) ($MN)
Table 84 Middle East & Africa Brain Tumor Drugs Market Outlook, By Meningioma (2020-2028) ($MN)
Table 85 Middle East & Africa Brain Tumor Drugs Market Outlook, By Glioblastoma (2020-2028) ($MN)
Table 86 Middle East & Africa Brain Tumor Drugs Market Outlook, By Glioma (2020-2028) ($MN)
Table 87 Middle East & Africa Brain Tumor Drugs Market Outlook, By Drugs (2020-2028) ($MN)
Table 88 Middle East & Africa Brain Tumor Drugs Market Outlook, By Bevacizumab (2020-2028) ($MN)
Table 89 Middle East & Africa Brain Tumor Drugs Market Outlook, By Temozolomide (2020-2028) ($MN)
Table 90 Middle East & Africa Brain Tumor Drugs Market Outlook, By Other Drugs (2020-2028) ($MN)
| ※参考情報 脳腫瘍治療薬は、脳に発生する腫瘍を治療するために使用される医薬品です。脳腫瘍は良性または悪性の腫瘍が含まれ、患者に様々な症状や合併症を引き起こす可能性があります。脳腫瘍の治療には外科手術、放射線治療、化学療法など多角的なアプローチが取られますが、その中でも化学療法に使われる治療薬は重要な役割を果たします。 脳腫瘍治療薬には主に3つの大きな種類があります。一つ目はアルキル化剤です。この薬剤は、がん細胞のDNAに直接結合し、細胞分裂を妨げることで腫瘍を縮小させる働きを持っています。代表的な薬剤には、テモダール（テモゾロマイド）などがあります。テモダールは特に悪性神経膠腫（グリオーマ）に有効であり、経口投与が可能なため患者にとって扱いやすいという特徴があります。 二つ目は抗代謝薬です。抗代謝薬は、正常な細胞とがん細胞の間で必要とされる物質の代謝を阻害することによって、がん細胞の増殖を抑える薬です。メトトレキサートやフルオロウラシルなどがこのカテゴリに含まれます。脳腫瘍においては、主に中枢神経系の腫瘍に対して使用されます。 三つ目は分子標的薬です。これらは特定の遺伝子やタンパク質を標的にすることで、がん細胞の生存や増殖を阻害します。ウィルスを利用した治療法や免疫チェックポイント阻害薬も含まれます。これらの薬剤は比較的新しいもので、がん細胞の個々の特性に応じて治療を行うことができるため、より効果的な治療が期待されています。具体的な薬剤としては、ニボルマブやダーボリマブなどがあります。 脳腫瘍治療薬の用途は多岐にわたり、まずは主に腫瘍の縮小を目指すものとして使用されます。また、手術後の再発防止や、他の治療法と組み合わせて効果を高めるために用いることもあります。治療薬の選択は腫瘍の種類や進行度、患者の全身状況によって異なるため、専門医による適切な診断と治療計画が求められます。 関連技術としては、薬剤の投与方法や新たな治療法の開発が挙げられます。近年では、腫瘍部位に薬剤を直接届けるためのナノテクノロジーの利用が進んでおり、これにより副作用を抑えつつ効果的な治療が期待されています。また、個別化医療の進展により、患者の遺伝子情報に基づいたターゲット療法が実現しつつあります。 脳腫瘍治療薬の開発においては、臨床試験の重要性も忘れてはなりません。新しい薬剤の有効性や安全性を確認するためには、さまざまな段階の臨床試験を経る必要があります。これにより、治療の選択肢が増え、より多くの患者がより良い治療を受けることができるようになります。 最後に、脳腫瘍治療薬の研究は日進月歩で進んでおり、新たな治療法や薬剤の誕生が期待されています。医療技術の進化とともに、より効果的で安全な治療法が確立されることを通じて、脳腫瘍患者のQOL（生活の質）の向上が図られることが望まれます。これからも医療現場では、脳腫瘍に対する治療薬の研究開発が推進されていくことと思います。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
